Recombinant Human Albumin(rHA)

With the rapid advancement of fields including cell and gene therapy (CGT), vaccine development and regenerative medicine, market demand for safe, stable and scalably supplied cell culture raw materials has been growing steadily. As a key component of serum‑free and animal‑free culture systems, recombinant human serum albumin (rHSA) is gradually emerging as a core raw material for industrial development. From multiple dimensions such as industrial trends, technical advantages and market applications, this paper explores the vital role of domestic recombinant human serum albumin in advancing the industrialization of cell therapy.

Ⅰ. Industrial Upgrading: From Plasma‑Derived to Recombinant, Animal‑Free Formulation an Inevitable Trend

Traditional cell culture heavily relies on animal serum or plasma‑derived proteins. However, their industrial applications have increasingly exposed prominent drawbacks such as significant batch‑to‑batch variability, risks of pathogen contamination, and unstable supply chains.
Driven by regulatory policies including the “818” guideline, the biopharmaceutical industry has raised higher standards for source compliance, quality controllability and animal‑free production of culture medium raw materials. Core requirements for raw materials in cell therapy industrialization are as follows:

• Safety: Eliminate potential contamination from viruses, prions and other hazards, and reduce risks of immunogenicity.
• Traceability: Ensure clear and controllable production processes and raw material sources to meet regulatory requirements such as GMP.
• Batch Consistency: Guarantee high uniformity across different batches to secure stability and reproducibility of manufacturing processes.
• Scalable Supply: Meet sustained and large‑scale raw material demands from research and development to commercial‑scale production.

Against this backdrop, adopting chemically defined, animal‑free culture media has become an industry consensus. With its well‑defined composition and non‑animal production route, recombinant human serum albumin (rHSA) serves as an ideal alternative to plasma‑derived albumin for constructing serum‑free culture systems.

Ⅱ. Technical Analysis: Advantages of Recombinant Pichia pastoris Expression System

Anrate adopts the mature recombinant Pichia pastoris expression system to produce recombinant human serum albumin (rHSA). Widely applied in the biopharmaceutical industry, this system features high expression efficiency, suitability for high‑density fermentation and relatively controllable production costs, making it one of the ideal platforms for large‑scale recombinant protein production.
Core advantages of rHSA produced via the Pichia pastoris‑based system are as follows:

• Animal‑free Origin: It fundamentally eliminates contamination risks of viruses, prions and other pathogens potentially brought by animal‑ or human‑blood‑derived raw materials, so as to improve product safety.
• High Purity and Consistency: Standardized fermentation and multi‑step purification processes ensure the product purity exceeds 99% with minimal batch‑to‑batch variation, meeting stringent stability requirements for industrial manufacturing.
• Defined Structure and Function: Recombinant human serum albumin has a molecular structure nearly identical to native albumin newly synthesized in the human liver, and possesses equivalent biological functions such as maintaining osmotic pressure and transporting nutrients as a carrier.

Ⅲ. Commercialization Prospects: Parallel Advancement of Production Capacity and Quality Validation to Break Raw‑Material Supply Bottlenecks

For cell therapy and biopharmaceutical enterprises in the industrialization stage, a stable and reliable raw‑material supply chain is one of the key factors determining their successful commercialization.
Anrate’s annual production capacity of 50 tons of recombinant human serum albumin (rHSA) marks the initial formation of large‑scale supply capacity for domestically produced key biological raw materials. More importantly, its product quality has undergone clinical validation under the highest standards.
Anrate’s recombinant human serum albumin injection has been approved for marketing in Russia and Kyrgyzstan, and has completed Phase III clinical trials in China. These outcomes fully prove its excellent safety and efficacy both as a pharmaceutical excipient and an independent drug, providing strong confidence guarantee for downstream enterprises to select high‑quality raw materials.

Core Applications of Recombinant Human Serum Albumin in the Cell Industry

• Cell and Gene Therapy: In the culture of CAR‑T cells, NK cells, stem cells and others, it acts as a protective agent to reduce cell damage from shear stress, and functions as a carrier to facilitate nutrient absorption and improve cell expansion efficiency.
• Vaccine Production: It serves as a stabilizer to protect antigen activity during the manufacture of viral or recombinant protein vaccines.
• Serum‑Free Culture Medium Development: As a core functional component, it replaces serum‑derived albumin to develop customized chemically defined culture media.
  Biopharmaceuticals: Used as a stabilizer and excipient in the production and formulation development of recombinant protein drugs, it extends product shelf life.
  Compared with imported products, domestic recombinant human serum albumin presents significant advantages in supply stability, delivery lead time and cost control. It helps lower production costs for domestic biopharmaceutical enterprises and accelerates product launch progress.

Ⅳ. Conclusion: Domestic Recombinant Raw Materials Accelerate Cell Therapy Industrialization

The cell therapy industry is undergoing a profound transformation from laboratory‑based R&D to large‑scale manufacturing. In this process, safe, stable and scalably supplied recombinant protein raw materials, particularly recombinant human serum albumin (rHSA), have become one of the core infrastructures driving industrial progress.

Represented by Anrate, domestic enterprises have mastered core technologies for recombinant protein expression and large‑scale production. With product quality validated by successful clinical trials and international market access, they are breaking the import monopoly of key biological raw materials, laying a solid foundation for the self‑reliance, controllability and long‑term development of China’s biopharmaceutical industrial chain.

Ⅴ. About Beijing Anrate Biotechnology Co., Ltd.

Beijing Anrate Biotechnology Co., Ltd. specializes in providing high‑quality, large‑scale‑manufactured recombinant protein raw material solutions for global biotechnology enterprises and life science research institutions. At present, its product portfolio covers recombinant human serum albumin (rHSA) and transferrin. All products are produced via animal‑free manufacturing processes and subject to rigorous quality control, ensuring stable and reliable core raw material support for sectors including cell therapy, biopharmaceuticals and culture medium development.

Important Notice